 |
(Photo= Yonhap news) |
[Alpha Biz= Reporter Kim Jisun] Hanmi Pharmaceutical Group declared an end to shareholder disputes on July 10th, paving the way for discussions on next-generation management strategies.
Chairman Shin Dong-kook of Hanmi Precision and Director Lim Jong-yoon of Hanmi Science announced through a meeting held the previous day that "family discord within Hanmi Pharmaceutical Group has been dramatically resolved." This includes ending conflicts involving founder Chairman Lim Sung-ki.
Chairman Shin positively evaluated this resolution, emphasizing discussions with brothers Lim Jong-yoon and Lim Jong-hoon on integrating responsible management, professional management, and governance to propel Hanmi Pharmaceutical Group into a global enterprise. They also highlighted plans to move away from a vertical management structure of chairmen and CEOs, opting instead to utilize committees, advisory boards, and expert management teams to invest extensively in human resources to achieve valued outcomes promptly.
This decision marks a pivotal shift towards long-term stability and growth for Hanmi Pharmaceutical Group, and the evolution of their management strategy will be closely watched in the coming years.
AlphaBIZ Kim Jisun(stockmk2020@alphabiz.co.kr)
